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Drug-resistant tuberculosis (DR-TB), defined as TB with 
at least rifampicin resistance, is increasing in preva-
lence and incidence worldwide.[1] South Africa (SA) has 
reported some of the highest numbers of DR-TB cases 
globally: in 2012 alone there were 14 161 laboratory-
notified cases of multidrug-resistant TB (MDR-TB) and 1 545 cases of 
extensively drug-resistant TB (XDR-TB).[2] Regimens available for DR-TB 
are expensive, toxic, and require a minimum treatment duration of 20 
months. In addition, currently available medications often cause multiple 
side-effects that impact on patients’ ability to maintain their usual daily 
activities.[3] The burden of treatment regimens contributes to poor DR-TB 
programme outcomes, including high rates of loss from treatment (LFT) 
and stagnant treatment success rates. A study conducted in the Western 
Cape Province, SA, found an LFT rate of 27%, which is comparable to 
LFT rates observed in other DR-TB treatment cohorts in SA.[4] National 
Department of Health (NDoH) data from 2012 reflect a 40% treatment 
success rate for MDR-TB and less than 20% treatment success for XDR-
TB.[2] It is imperative that strategies to provide structured patient support 
are developed and implemented to promote retention in care.
Setting
Khayelitsha, a township in the Western Cape, is home to 
approximately 500 000 people and has one of the highest rates of 
HIV and TB among subdistricts in the country. It was determined 
that there were 989 cases of DR-TB diagnosed in Khayelitsha 
from 2003 through 2010, 200 of which were diagnosed in 2010. In 
response to the growing burden of DR-TB in Khayelitsha, Médecins 
Sans Frontières (MSF) collaborated with City of Cape Town 
Department of Health (CCTDoH) and provincial health services 
in 2007 to pilot a decentralised model of care in which primary 
healthcare clinicians initiate and manage treatment of patients 
diagnosed with DR-TB at Khayelitsha-based clinics. The prevailing 
model of care for DR-TB previously involved centralisation of 
treatment to 45 specialised hospitals in SA, which hindered the 
ability to provide longitudinal support to DR-TB patients and their 
families in their local community. In contrast, decentralisation to 
primary care enabled patient support to form a major component 
of the overall model of care.[5] Two dedicated lay DR-TB counsellors 
were employed to provide education and support to DR-TB patients 
managed at 11 primary care clinics in the subdistrict. Since 2011 
the model has been managed by the CCTDoH, and various aspects 
of the model have been adopted and implemented across other 
subdistricts in the Western Cape. In 2012, MSF, together with the 
CCTDoH, developed a more structured, standardised, patient-
centered approach to counselling DR-TB patients, placing equal 
emphasis on treatment literacy and adherence support.
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In response to the growing burden of drug-resistant tuberculosis (DR-TB) in South Africa (SA), Médecins Sans Frontières (MSF), with local 
government health departments, piloted a decentralised model of DR-TB care in Khayelitsha, Western Cape Province, in 2007. The model 
takes a patient-centred approach to DR-TB treatment that is integrated into existing TB and HIV primary care programmes. One essential 
component of the model is individual and family counselling to support adherence to and completion of treatment. The structured and 
standardised adherence support sessions have been compiled into a DR-TB counselling toolkit. This is a comprehensive guide that focuses 
on DR-TB treatment literacy, adherence strategies to encourage retention in care, and provision of support throughout the patient’s long 
treatment journey. Along with other strategies to promote completion of treatment, implementation of a strong patient support component 
of DR-TB treatment is considered essential to reduce rates of loss from treatment among DR-TB patients. We describe our experience from 
the implementation of this counselling model in a high DR-TB burden setting in Khayelitsha, Cape Town, SA.
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Objective
A policy of decentralised management of 
DR-TB in SA was endorsed by the NDoH 
in 2011. Although welcomed for its priori-
tisation of decentralisation nationally, it 
lacks specific information on how to provide 
structured patient support and counselling 
despite its recommendation to provide these 
services to patients. The DR-TB counselling 
toolkit aims to provide guidance on how to 
provide patient support to promote adherence 
to difficult treatment regimens, to encourage 
retention in care, and to increase the 
likelihood of successful treatment outcomes.
The intervention
The counselling toolkit is a comprehensive 
guide that provides patients with support 
throughout the duration of their treatment. 
It aims to encourage patients to take owner-
ship of their treatment. Specific counselling 
session plans have been included in the 
toolkit that provide structured scripts of 
simple key points to convey to patients, 
Table 1. Timing of DR-TB counselling sessions[6]
Session Target Rationale Timing and location Session content
Resource 
materials
Session 1 Newly diagnosed 
DR-TB patients
Provide the patient with 
information regarding 
DR-TB to promote 
insight about their 
disease, adherence to 
treatment, and ownership 
of their treatment journey
To plan with the 
counsellor how to 
overcome possible 
barriers to treatment 
adherence
First day of treatment 
initiation
Clinic
Treatment literacy
Basic TB and DR-TB information 
including definitions, when and 
where to take treatment, and clinic 
visits; basic awareness of side-
effects and other treatment-related 
challenges; basic infection control
Adherence steps
Step 1: Getting to appointments
Step 2: Dealing with side-effects
Step 3: Getting support at home
Step 4: Getting support at the clinic
Step 5: Audiometry screening
Identify three reasons to stay 
healthy and alive
Session plan – 
session 1
Flip chart
Adherence plan 
Stickers
Session 2 
(may be 
com bined 
with  
session 3)
DR-TB patients 
who have received 
counselling 
session 1
Provide the patient with 
information regarding 
DR-TB to promote 
insight into their 
disease and adherence 
to treatment, and allow 
patient to take ownership 
of the treatment journey 
as they plan with the 
counsellor how to 
overcome possible 
barriers to adherence to 
treatment 
Within 1 week of 
treatment initiation
Home or clinic
Treatment literacy
Basic information regarding 
adherence and what to expect if 
adherence is poor; discussing the 
importance of identifying drugs 
and dosages; definitions of sputum 
and culture conversion
Adherence steps
Step 6: Preventing future mistakes 
and completing the treatment 
journey
Step 7: Identifying a treatment 
partner
Step 8: Communicating with the 
treatment team
Step 9: How to manage weekend 
doses
Step 10: Reminder strategies
Session plan – 
session 2
Flip chart
Adherence plan 
Stickers
Continued ...
Session 1
Session 2
Session 3
Home visit
Session 4
XDR session
Milestone
Treatment start
<1 week later
<1 month later
2nd-line DST result
Injectable phase Continuation phase
Treatment interruption >2 weeks at any point through treatment
Treatment
interruption session
Treatment
interruption follow-
up
Treatment
failure
Palliative
session
Fig. 1. Overview of the counselling sessions.[6] (DST = drug susceptibility testing.)
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Table 1. (continued) Timing of DR-TB counselling sessions[6]
Session Target Rationale Timing and location Session content
Resource 
materials
Session 3 
(may be 
combined 
with  
session 2)
DR-TB patients 
who have received 
counselling 
session 2
Provide DR-TB 
information to the 
family and the patient, 
encouraging the 
family to support the 
patient; DR-TB contact 
identification, screening 
and infection control 
advice
Within the first month 
of treatment initiation
Home (if the patient 
refuses a home visit, 
this session can be 
done in the clinic 
with a family member 
joining the patient)
Treatment literacy
Basic TB and DR-TB information: 
TB infection control and how TB 
is spread; time off work or school; 
patient journey; details of those 
at risk of DR-TB and contacts 
in the home; TB and pregnancy; 
traditional medication and alcohol 
use with treatment
Adherence steps
Step 11: How to protect my family
Step 12: How to deal with 
substance abuse
Step 13: Managing unplanned trips
Session plan – 
session 3
Flip chart
Adherence plan
Session 4 DR-TB patients 
who have 
completed the 
intensive phase
Congratulate the patient 
and revise treatment 
literacy messages and 
adherence steps to ensure 
ongoing adherence 
(also inform patient 
of potential for self-
administered treatment 
(SAT) in some settings)
Completion of 
intensive phase
Clinic
Revision of treatment literacy 
messages
See sessions 1 - 3
Revisit adherence steps
See sessions 1 - 3
Session plan – 
session 4
Flip chart
Adherence 
plan that was 
completed 
post treatment 
initiation
Treatment 
interruption 
session
Patients who 
interrupted 
DR-TB treatment 
for ≥2 consecutive 
weeks or who 
frequently 
interrupt 
treatment for 
short time periods 
Promote adherence to 
treatment and prevent 
LFT
As soon as the patient 
has interrupted 
DR-TB treatment for 
2 consecutive weeks, 
or if the patient 
frequently interrupts 
treatment for short 
time periods
Clinic or home
Treatment literacy
What is adherence, what happens 
if you take your treatment, and 
what happens if you stop taking 
your treatment
Adherence steps
Step 1: Reminder strategies
Step 2: Getting to the clinic
Step 3: Getting support at home
Step 4: DR-TB support at the clinic
Step 5: Dealing with side-effects
Step 6: Dealing with substance use
Step 7: Completing your treatment 
journey
Session plan – 
treatment 
interruption 
session
Flip chart
Adherence plan
Treatment 
interruption 
follow-up 
sessions
Patients who 
received the 
treatment 
interruption 
session
Monitor adherence on 
a frequent basis and 
improve the patient-
healthcare worker 
relationship
One week after the 
treatment interruption 
counselling session
Clinic
Follow-up session
Monitor goals achieved, set new 
goals
Adherence plan
Nurse 
monitoring 
document
XDR-TB 
session
Patients with a 
pre-XDR or XDR-
TB diagnosis
Educate the patient 
on pre-XDR and XDR 
diagnosis, discuss potential 
future treatment options 
and limitations (the 
clinician will continue 
this discussion), create an 
awareness of palliative care
As soon as possible 
after second-line 
resistance has been 
detected
Clinic
Treatment literacy
Adherence assessment
Step 1: Confirming the patient’s 
support system at home
Step 2: Reviewing contacts for 
screening
Step 3: SOS plan for emergencies
Session plan – 
XDR-TB session
Adherence 
assessment
Palliative 
care session
Patients in whom 
DR-TB treatment 
has failed, 
and have been 
identified as such 
by a clinician
Understanding their 
diagnosis and prognosis, 
future treatment and 
psychosocial support 
options
As soon as the patient 
is identified by a 
clinician as a patient 
in whom DR-TB 
treatment has failed
Home or clinic
Explanation about current 
diagnosis; what happens with 
treatment of other chronic diseases 
or conditions; how to travel safely 
if the patient intends to migrate
Session plan – 
palliative care 
session
Relevant facility 
contact details
Referral letter 
from clinician
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and steps they should follow to overcome commonly experienced 
barriers to adherence. The initial four sessions are conducted during 
the intensive phase of treatment (the first three should be conducted 
within the first 4 weeks of treatment initiation, one of which must be 
a home visit), with the goals of treatment literacy, stepwise adherence 
planning, family involvement, contact tracing and infection control 
advice. In addition to these initial sessions, counselling sessions can 
occur at any time during treatment to address treatment interruption, 
the diagnosis of XDR-TB, and treatment failure and palliative care. 
These additional sessions are particularly important, as they provide 
detailed scripts for lay counsellors or professional healthcare workers 
to address very sensitive topics with patients and their families 
should treatment not yield a successful outcome. Recognising the 
importance of quality assurance, a counsellor competency assessment 
for supervisors has also been included in the toolkit.[6] Fig. 1 provides 
a summary of the timing of the various DR-TB sessions in relation to 
the patient’s journey towards DR-TB treatment completion. Table 1 
provides an overview of the contents of the various counselling 
sessions provided by the DR-TB counsellor to the patient.
While challenges in the implementation of this patient support model 
can be anticipated, including human resource needs for skilled lay 
counsellors and their supervision, the structured nature of the approach 
supports formalised training and monitoring of counsellors and their 
supervisors. It is further possible to implement counselling sessions in a 
phased manner to slowly build capacity towards implementing the more 
specialised XDR-TB and palliative care sessions. 
The infrastructure required for the implementation of this toolkit 
includes four essential components: DR-TB counselling session guides 
for both the counsellors and their supervisors; adherence plans for 
patients (Fig. 2); DR-TB flipcharts to use as supportive educational 
tools during counselling sessions; and a structured training programme 
for counsellors that contains the tools and exercises necessary to ensure 
standardised quality of counselling provided to patients.
Conclusions
The counselling toolkit was presented at the 4th Annual South 
African Tuberculosis Conference held in Durban, SA, on 10 - 13 
June 2014. At the conclusion of the conference, the counselling 
model was recognised for clinical excellence by the organising 
committee, reinforcing the importance of including a structured 
patient support component during decentralisation of DR-TB care 
to primary care level. The DR-TB counsellor is a critical member of 
the team providing care to patients with DR-TB. It is essential that all 
DR-TB clinicians, nurses, and counsellors work together to ensure 
comprehensive support for patients with DR-TB. This support is as 
essential as the pills patients are required to take every day, and must 
continue throughout the long DR-TB treatment journey.
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Fig. 2. Sessions 1 - 3 adherence plan for patients.[6]
Patient name:
My three reasons to stay healthy and alive:
1
2
3
Session 1 (date)
DR-TB education done
Adherence Step 1: Getting to appointments
How am I going to get to clinic every day
Backup plan to get to appointments daily
Adherence Step 2: Dealing with side-eects
My plan for minor side-eects is
My plan for side-eects that worry me is
Adherence Step 3: Getting support at home Agree to a home visit Yes No
Members of my support system
Who else can support me in my treatment
Adherence Step 4: Getting support at the clinic
Contact details of the clinic
Adherence Step 5: Getting to my audiometry screening appointments
How to remember audiometry appointments
How to get to my audiometry appointments
Backup plan to get to appointments
Session 2 (date)
DR-TB education done
Adherence Step 6: Preventing any future mistakes and completing my treament journey
What will I do if I make a mistake, and don’t come to the clinic for a while to take my treament
Adherence Step 7: Treatment partner
My treatment partner is
Adherence Step 8: Communicating with treatment team
My focal person in clinic is
Adherence Step 9: How to manage weekend doses
How will I remember to take my weekend medication
Where will I keep my weekend medication
Adherence Step 10: Reminder strategies
I will put my reminder stickers on
I will read my reasons for taking my treatment at
My other reminder tools are
Session 3 (date)
DR-TB education done
Adherence Step 11: How to protect my family
I will sleep
Adherence Step 12: Dealing with substance use
My plan to make sure I take my treatment if I used alcohol or drugs is
Adherence Step 13: Managing unplanned trips
My folder number
My regular travel location
The closest clinic at my  regular travel location is
GOAL: To be sputum–negative
